Apollo Micro Systems Q2 FY27 presentation: 72% revenue growth

Apollo Micro Systems reported Q2 FY27 consolidated revenue of ₹3,881.5 million, up 72.3% year over year, and PAT of ₹461.5 million, up 53.7%; its EBITDA margin expanded to 28.6%. The order book reached a record ₹17,650 million, with management targeting more than ₹20,000 million by March 2027 and standalone FY27 revenue growth guidance of 45%–50%; a potential MIGM order could lift the order book to ₹45,000–50,000 million. Shares rose 11.87% to $419.25, while execution of anticipated contracts remains a key risk.

Analysis

The key underwriting question is conversion quality, not the reported growth rate. The faster consolidated expansion than standalone warrants a bridge separating organic growth from acquired-business contribution; without it, extrapolating the headline pace risks overpaying for inorganic scale. Production mix is also a potential margin tailwind that may not persist as development work and new programs cycle through. The largest upside catalyst is formal award and execution of the anticipated large programs, but management’s projected order-book step-up is not equivalent to funded, scheduled revenue. Verify award notices, delivery milestones, customer advances, receivable aging, and cash conversion before capitalizing it.

Near term, the sharp share-price reaction and proximity to the high raise the bar for incremental buyers; a positive quarter can still be followed by multiple compression if orders slip or margins normalize. Over 1–3 months, the stated order milestones may sustain momentum, but delays would likely expose crowded growth expectations. Over 6–18 months, successful integration and delivery could broaden revenue beyond development programs; conversely, long working-capital cycles can absorb earnings growth and constrain returns even as reported profits rise. The structural defense-spending tailwind is supportive but does not eliminate contract timing or execution risk.

Key Decisions for Investors

• Do not chase the post-results gap on this evidence alone. Treat the company as a catalyst watch rather than a confirmed earnings compounder until order wins and cash conversion are independently visible.
• For existing exposure, retain only a risk-sized position into the next order milestones; reassess on formal awards, delivery schedules, and receivable/working-capital disclosures. A delayed award or worsening collections would weaken the thesis even if revenue remains strong.
• Consider a staged long entry only after a pullback or after a formal contract award, provided guidance is maintained and production margins hold without further deterioration in cash conversion. Do not assign the prospective MIGM order-book increase to base-case value before award confirmation.
• Request a standalone-to-consolidated revenue and profit bridge, acquired-business contribution, and order-book delivery/payment profile. If these are not disclosed, avoid extrapolating current growth or margin run rates; compare exposure with diversified Indian defense holdings rather than assuming single-company execution risk.